Sphingolipid Metabolism Cooperates with BAK and BAX to Promote the Mitochondrial Pathway of Apoptosis

Jerry E. Chipuk[1,*], **Gavin P. McStay**[2,7], **Archana Bharti**[1], **Tomomi Kuwana**[3,8], **Christopher J. Clarke**[4], **Leah J. Siskind**[5,6], **Lina M. Obeid**[5,6], and **Douglas R. Green**[2,*]

[1]Mount Sinai School of Medicine, Department of Oncological Sciences, One Gustave L. Levy Place, New York, NY 10029, USA

[2]St. Jude Children's Research Hospital, Department of Immunology, 262 Danny Thomas Place, Memphis, TN 38105, USA

[3]University of Iowa, Carver College of Medicine, Department of Pathology, 1161 Medical Laboratories, Iowa City, IA 52252, USA

[4]Medical University of South Carolina, Department of Biochemistry and Molecular Biology, 173 Ashley Street, Charleston, SC 29425, USA

[5]Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC 29401, USA

[6]Medical University of South Carolina, Department of Medicine, Division of General Medicine and Geriatrics, 114 Doughty Street, Charleston, SC 29425, USA

SUMMARY

Mitochondria are functionally and physically associated with heterotypic membranes, yet little is known about how these interactions impact mitochondrial outer-membrane permeabilization (MOMP) and apoptosis. We observed that dissociation of heterotypic membranes from mitochondria inhibited BAK/BAX-dependent cytochrome c (cyto c) release. Biochemical purification of neutral sphingomyelinases that correlated with MOMP sensitization suggested that sphingolipid metabolism coordinates BAK/BAX activation. Using purified lipids and enzymes, sensitivity to MOMP was achieved by in vitro reconstitution of the sphingolipid metabolic pathway. Sphingolipid metabolism inhibitors blocked MOMP from heavy membrane preparations but failed to influence MOMP in the presence of sphingolipid-reconstituted, purified mitochondria. Furthermore, the sphingolipid products, sphingosine-1-PO$_4$ and hexadecenal, cooperated specifically with BAK and BAX, respectively. Sphingolipid metabolism was also required for cellular responses to apoptosis. Our studies suggest that BAK/BAX activation and apoptosis are coordinated through BH3-only proteins and a specific lipid milieu that is maintained by heterotypic membrane-mitochondrial interactions

*Correspondence: jerry.chipuk@mssm.edu (J.E.C.), douglas.green@stjude.org (D.R.G.) .
[7]Present address: Columbia University, Department of Biological Sciences, 1212 Amsterdam Avenue, 718 Fairchild Center, New York, NY 10027, USA
[8]Present address: La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA

INTRODUCTION

Mitochondria are dynamic organelles that interact with each other and heterotypic intracellular membrane compartments, such as the endoplasmic reticulum (ER) (Csordas et al., 2006; de Brito and Scorrano, 2008). It is proposed that mitochondria are structurally and functionally tethered to organelles via proteins that reside in the outer mitochondrial membrane (OMM), and that these organelle-organelle interactions form unique biochemical and physical loci that regulate lipid biosynthesis, lipid transport, and intra-organellar Ca^{2+} signaling (Hayashi et al., 2009; Scorrano et al., 2003; Walter and Hajnoczky, 2005). An area of particular interest is the impact of organelle communication on apoptosis.

The mitochondrial pathway of apoptosis is dependent upon the BCL-2 family for the release of proapoptotic factors (e.g., cyto c) from the mitochondrial intermembrane space (IMS), via the process of mitochondrial outer-membrane permeabilization (MOMP) (Chipuk et al., 2010). The BCL-2 family is divided into three functional groups based on their composition of up to four BCL-2 homology domains (BH1-4 domains) (Chipuk et al., 2010). Anti-apoptotic BCL-2 proteins (e.g., BCL-xL) function to directly bind and inhibit the proapoptotic BCL-2 proteins. The proapoptotic members are divided into two classes. The effector molecules (e.g., BAK, BAX) directly engage MOMP by creating proteolipid pores responsible for cyto *c* release (Kuwana et al., 2002; Lindsten et al., 2000; Wei et al., 2000; Wei et al., 2001). The BH3-only proteins function in distinct cellular stress pathways to either directly activate BAK/BAX-dependent MOMP (e.g., BID), or by inhibiting the anti-apoptotic repertoire (e.g., BAD), which alters sensitivity to the direct activators and effectors (Chipuk et al., 2008; Kuwana et al., 2005; Letai et al., 2002).

Sphingolipid metabolism also regulates apoptosis, but how sphingolipids mechanistically intersect with BCL-2 family function remains obscure (Hannun and Obeid, 2008). Apoptotic inducers promote alterations in sphingolipid profiles, in particular ceramide profiles (Taha et al., 2006b). Exogenous ceramides applied to cells promotes apoptosis (Obeid et al., 1993); and genetic or pharmacological inhibition of ceramide production can result in apoptotic resistance (Alphonse et al., 2004; Liu et al., 2004; Pchejetski et al., 2005; Rodriguez-Lafrasse et al., 2002; Taha et al., 2006a)(Dai et al., 2004; Deng et al., 2008; Mesicek et al., 2010). A challenge remains to determine if sphingolipids and the BCL-2 family cooperate to regulate MOMP. Here we show that mitochondria actively maintain a sphingolipid milieu that promotes BAK/BAX function and apoptosis.

RESULTS

Microsomes Restore Mitochondrial Sensitivity to Direct Activator Stimulation

The isolation of heavy membrane (HM) fractions usually results in mitochondria that are contaminated with ER markers. Using a refinement of a published protocol (Csordas et al., 2006), we eliminated the majority of ER contamination and were able to obtain a highly pure mitochondrial population (Figures S1A-B). This purified fraction was designated *mitochondria*, whereas the subsequent light membrane, heterotypic fraction was termed *microsomes* (μS). We then examined the influence of these heterotypic species on mitochondrial sensitivity to recombinant caspase-8 cleaved BID (C8-BID)-induced BAK activation and cyto *c* release. BAK is the effector molecule under investigation in these experiments because C57Bl/6 liver HM fractions only contain BAK due to its integration within the OMM. BAX is a cytosolic effector protein and does not copurify using standard HM isolation techniques. In Figure 1A, HM fractions were treated with C8-BID and this resulted in a dose-dependent release of cyto *c* as measured by a change in localization from the pellet (p) to the supernatant (s). In comparison, mitochondria purified from the HM

fraction were treated with the same doses of C8-BID and demonstrated reduced cyto c release, requiring 10-20 fold higher C8-BID concentrations to achieve minimal release.

To determine if resistance to C8-BID induced cyto c release was due to decreased binding of C8-BID to mitochondria, we incubated the HM and mitochondrial fractions with C8-BID, washed the fractions, and subjected them to western blot for associated BID. Both fractions bound equal amounts of the BID p15 fragment suggesting the decreased sensitivity of mitochondria was independent of BID association (Figure 1B). Direct activator BH3-only protein function can be mimicked by short peptides derived from the BH3 domains of BID and BIM (referred to as BID BH3 and BIM BH3) (Kuwana et al., 2005; Letai et al., 2002). We compared the responses of the HM fraction versus mitochondria to BID BH3 and BIM BH3 induced cyto c release. The HM fraction treated with BID BH3 or BIM BH3 demonstrated greater sensitivity to cyto c release compared to mitochondria (Figure 1C), suggesting the effect was not specific to BID. To ensure that the purification of mitochondria did not alter their integrity, we measured their ability to respire and compared their rates of O_2 consumption to the original HM fraction. The HM fraction and mitochondria exhibited similar rates of O_2 consumption (Figure S1A, available online), and mitochondria appeared normal by electron microscopy (Figure S1B).

When mitochondria were purified from the HM fraction, there was a loss of 30%–40% of protein, which was recovered in the resulting μS fraction. We hypothesized that the μS fraction contained an activity required for maintaining sensitivity to C8-BID. Mitochondria alone incubated with C8-BID did not release cyto c, but the addition of μS promoted dose-dependent release of cyto c (Figure 1D). The combination of μS and BID BH3 also promoted cyto c release (Figure 1D). For both C8-BID and BID BH3 cooperation with μS, BCL-xL blocked cyto c release suggesting that microsome-regulated MOMP proceeded through BAK (Figure 1D). Cyto c and BAK levels did not change after addition of μS (Figures 1E and 1F).

As low concentrations of C8-BID (0.1 nM) did not induce MOMP in HM fractions, but the addition of solubilized mS synergized with C8-BID to produce robust MOMP (Figures 1A and 1D and Figure S1C), we subjected μS proteins to the enrichment protocol shown in Figure 1G and monitored synergy with C8-BID (Figures S1C-E, left). Peptide analysis of the final, enriched preparation revealed the presence two neutral sphingomyelinases (N-SMase; also referred to as SM phosphodiesterases), SMPD3 and SMPD4. The MOMP-promoting fractions were then examined for N-SMase activity by ^{14}C-SM hydrolysis (Figures S1C-E, right). N-SMase activity correlated with fractions that synergized with C8-BID to promote MOMP. We therefore directly examined the effects of N-SMases on MOMP.

A Neutral Sphingomyelinase Activity Cooperates with the BCL-2 Family to Promote MOMP

To determine if SMPD3 or SMPD4 uniquely promoted MOMP, we compared SMPD2, 3, and 4 for their ability to sensitize WT HM fractions for C8-BID induced cyto c release. SMPD2, SMPD3, and SMPD4 were in vitro transcribed and translated (IVTT), and each was tested for ^{14}C-SM hydrolysis (Figures 2A and 2B). We next analyzed the IVTT proteins for their abilities to promote C8-BID induced cyto c release. SMPD2-4 cooperated with C8-BID to promote MOMP, which was blocked by either the N-SMase inhibitor GW4869 or BCL-xL (Figure 2C). These data suggest that mitochondria and C8-BID cooperate with a general N-SMase activity. Furthermore, inhibition by GW4869 and BCL-xL confirmed that MOMP was promoted via SMase activity and through the activation of BAK, respectively (Figures 2B and 2C).

To further examine the cooperation between C8-BID and sphingolipid metabolism, we added a suboptimal concentration of C8-BID to WT HM fractions in the presence of either a ceramide synthase inhibitor in the de novo synthetic pathway (FB1), which does not rely on a SMase; or an inhibitor of SM synthase, D609, which can demonstrate coupling between SMases and SM synthases. A suboptimal concentration of C8-BID promoted a small amount of cyto *c* release that was inhibited by D609, but not FB1, further suggesting a potential role for a SMase in MOMP (Figure 2D). As an additional control, we compared WT and acid SMase knockout (*asm*$^{-/-}$) HM fractions for their ability to sensitize WT HM fractions for MOMP as in figure S1E, and observed equivalent MOMP-promoting activities (Figures S2A–S2C). We next tested an N-SMase from *B. cereus* (bSMase) for its ability to cooperate with C8-BID. As shown in Figure 2D, bSMase promoted a small but detectable amount of cyto *c* release in WT HM; but when bSMase was titrated in the presence of C8-BID, the release of cyto *c* was robust and complete.

The above results suggest that removal of contaminating membranes from mitochondria reduced sensitivity to C8-BID induced MOMP. We hypothesized that mitochondrial purification from the HM fraction removed a SMase activity that was necessary for normal sensitivity to C8-BID. To address this, total liver homogenate, the HM fraction, and mitochondria were compared for ^{14}C-SM hydrolysis. Approximately two-thirds of cellular N-SMase activity was lost during HM purification, yet the remaining N-SMase activity was present in the HM fraction. Limited proteolysis and further purification of mitochondria reduced the activity to below 5% (Figure 2E). This suggests that the N-SMase activity that cooperates with C8-BID is not mitochondrial in origin, but is present in the heterotypic membranes. To ensure that the purification protocol did not degrade or inhibit the released N-SMase activity, we analyzed the HM fraction, released heterotypic membranes, and mitochondria during a time course of proteolysis for 14C-SM hydrolysis. N-SMase activity in the HM fraction was released in a time-dependent manner, remained active, and was recoverable (Figure 2F). As controls, we monitored an ER luminal marker (PDI) and cyto *c* to ensure appropriate loss of heterotypic membrane species and equal analysis of mitochondria, respectively (Figure 2F).

We chose to focus on SMPD3 as the significant MOMP-promoting activity because it was consistently identified in our assays (Figure 1G) and was amenable to recombinant protein production (Figure 2I). We detected very few SMPD4 peptides in our mass spectroscopy analyses and could not produce recombinant SMPD4 after numerous attempts. Recombinant mouse SMPD3 was tested for ^{14}C-SM hydrolysis and demonstrated significant activity (Figure 2I). SMPD3 was then analyzed for its ability to cooperate with C8-BID to promote MOMP. Using a WT HM fraction, we titrated suboptimal concentrations of C8-BID in the presence of increasing SMPD3. C8-BID at 0.05-0.5 nM promoted minimal cyto *c* release, but this was enhanced by the additional of SMPD3. For example, 0.5 nM C8-BID treatment of the HM fraction released only small amounts of cyto c; this was enhanced to nearly 100% release in the presence of all SMPD3 concentrations tested (Figure 2G). As WT HM fractions contain only BAK, we sought to examine the regulation of BAX-dependent MOMP by using a purified *bak*$^{-/-}$*bax*$^{-/-}$ HM fraction. The addition of C8-BID and BAX reconstituted BAX-dependent MOMP in the *bak*$^{-/-}$*bax*$^{-/-}$ HM fraction (Figure 2H). A concentration of C8-BID (1 nM) that was alone insufficient to promote MOMP was then added to BAX in the presence of increasing SMPD3. The addition of SMPD3 cooperated with 1 nM C8-BID and BAX to promote substantial MOMP (Figure 2H). For both BAK and BAX-dependent MOMP, the addition of BCL-xL blocked C8-BID induced cyto *c* release (Figures 2G and 2H).

Pharmacological Inhibition of Sphingolipid Metabolism Blocks MOMP

We next investigated a panel of SM pathway inhibitors to examine their effects on C8-BID induced BAK activation. The SM pathway products, enzymes, and inhibitors relevant to this study are summarized in Figure 3A. WT HM fractions were preincubated with increasing doses of GW4869, NOE (ceramidase inhibitor), MAPP (ceramidase inhibitor), SKI (sphingosine 'SPH' kinase inhibitor), DMS (SPH kinase inhibitor), DOP (sphingosine-1-PO_4 'S1P' lyase inhibitor), or THI (S1P lyase inhibitor) prior to the addition of C8-BID and analyzed for cyto c release (Figures 3B–3D). While none of the drugs alone promoted MOMP; GW4869, NOE, MAPP (Figure 3B), SKI, and DMS (Figure 3C) completely blocked C8-BID induced cyto c release. In the case of BAK-dependent MOMP, DOP and THI did not influence C8-BID induced cyto c release (Figure 3D).

These data suggest that S1P synthesis is essential for sensitivity of BAK activation in response to C8-BID. To test this hypothesis, a WT HM fraction and subsequent mitochondria were purified in the presence of DOP and THI to prevent S1P degradation. Mitochondria purified in the presence of DMSO were incubated with increasing doses of C8-BID and demonstrated resistance to C8-BID induced cyto c release (Figure 3E). However, mitochondria purified in the presence of DOP and THI demonstrated C8-BID sensitivity similar to the HM fraction (Figure 3E). Indeed, mitochondrial purification in the presence of either DOP or THI prevented the degradation of S1P and levels remained markedly higher compared with mitochondria purified in the presence of DMSO (Figure 3F and Figure S3A). The resulting concentrations of mitochondrial S1P following DOP or THI inhibition equaled approximately 1.8 µM and 0.42 µM, respectively. We based these calculations on 50 µg of mitochondrial protein per 50 µl MOMP reaction equals 10 nmole of total lipid P_i (Wagner and Rafael, 1977). As an example for DOP treatment, 91.118 pmoles of S1P/nmole lipid P_i was detected; therefore, 911.18 pmoles of S1P equals 1.8 µM S1P per 50 µl reaction.

As an additional control for the inhibitor studies, we analyzed GW4869, NOE, and MAPP for their capacity to regulate C8-BID induced MOMP in the absence of pretreatment (same treatments as in Figure 3B). This control was done to ensure that pretreatment was necessary as inhibition of MOMP following simultaneous drug and C8-BID treatment would likely suggest these drugs are not directly affecting sphingolipid levels (Figure S3B).

The same panel of SM pathway inhibitors was tested for their influence on C8-BID induced BAX activation using $bak^{-/-}bax^{-/-}$ HM fractions. This fraction was preincubated with different doses of FB1, D609, GW4869, NOE, MAPP, SKI, DMS, DOP, or THI prior to the addition of BAX and C8-BID (Figures 3G and 3H). The inhibitors had no effect on the HM fraction in the absence of C8-BID and BAX (Figure 3G), but all the sphingolipid metabolism inhibitors blocked C8-BID plus BAX-induced cyto c release (Figure 3H). We performed the same assay as in Figures 3B–3D, but also probed for SMAC to ensure the effect is specific for MOMP and not cyto c mobilization (Figure S3C).

BAX-dependent cyto c release is associated with conformational changes at the amino terminus of BAX, which is recognized with the conformation-specific antibody, 6A7 (Hsu and Youle, 1997). To determine if the sphingolipid inhibitors blocked BAX conformational changes, we preincubated $bak^{-/-}bax^{-/-}$ HM with the highest doses of the drugs used in Figure 3H for 1 hr, prior to the addition of BAX and C8-BID. The reactions were lysed and subjected to 6A7 immunoprecipitation (IP). The addition of C8-BID to the DMSO-treated HM fraction lead to 6A7-positive BAX. However, pretreatment with D609, GW4869, NOE, MAPP, SKI, DMS, DOP, or THI, but not FB1, led to no 6A7-positive BAX (Figure 3I). Furthermore, the same sphingolipid inhibitors that prevent BAX structural rearrangements also lead to the inhibition of BAX oligomerization (Figure S3D). These data suggest that a

SM metabolic product beyond S1P is essential for sensitivity to C8-BID induced BAX activation (Figures 3H and 3I), which contrasts to the lipid requirement for BAK-dependent MOMP (Figure 3D).

Reconstitution of Sphingolipid Metabolism Replaces the Heterotypic Membrane Requirement for MOMP

To examine further if BAK and BAX-dependent cyto *c* release require different components of the SM pathway, we reconstituted the sphingolipid pathway with purified enzymes and lipids in the presence of WT or *bak*[-/-]*bax*[-/-] mitochondria. SM hydrolysis to ceramide was recapitulated by combining bSMase, SM, and WT mitochondria. After 1 hr incubation at 37°C, C8-BID was added. Reconstitution of SM hydrolysis alone did not promote MOMP, but the addition of C8-BID allowed for cyto *c* release, which was blocked by GW4869 (Figure 4A). The conversion of ceramide to SPH was recapitulated by combining recombinant N-acylsphingosine amidohydrolase 2 (ASAH2, neutral ceramidase), C16-Ceramide (C16), and WT mitochondria. After 1 hr incubation at 37°C, C8-BID was added. Reconstitution of ceramide hydrolysis alone did not promote MOMP, but the addition of C8-BID allowed for cyto *c* release, which was blocked by MAPP (Figure 4A). The conversion of ceramide to SPH was also recapitulated by combining SPH and WT mitochondria. SPH treatment alone did not promote MOMP, but the addition of C8-BID allowed for cyto *c* release, which was insensitive to both GW4869 and MAPP (Figure 4A). These data suggest that SPH is upstream of C8-BID induced BAK activation and MOMP.

Sphingolipid metabolites ranging from SM to *ortho*-phosphoethanolamine (OPEA) and hexadecenal (hex) were examined for their ability to sensitize WT mitochondria for C8-BID induced BAK activation. SM, C16, SPH, S1P, OPEA, and hex were titrated on WT mitochondria in the presence of C8-BID. The sphingolipids and C8-BID were added simultaneously to thwart the conversion of intermediates by mitochondrial sphingolipid enzymes. Based on our results in Figure 3F and the calculations detailed above, we used an average of the DOP and THI induced S1P concentrations (1.8 µM and 0.42 µM, respectively) as a benchmark for an approximate physiological concentration of sphingolipids to examine per assay (0.1, 0.5, and 1 µM). As shown in Figure 4B, the combination of S1P and C8-BID resulted in the complete release of cyto c. The same experiment was then conducted using *bak*[-/-]*bax*[-/-] mitochondria combined with BAX, and C8-BID induced BAX-dependent MOMP was reconstituted by the fatty aldehyde, hex (Figure 4D). None of the sphingolipid metabolites alone had an observable effect on *bak*[-/-]*bax*[-/-] mitochondria (Figure 4C); and the *bak*[-/-]*bax*[-/-] HM fraction responded to C8-BID and BAX as expected (Figure 4D). These results suggest that BAK and BAX-dependent MOMP require different components of the sphingolipid pathway: BAK cooperates with S1P, while BAX cooperates with hex.

To determine if hex promoted BAX activation and subsequent 6A7 positivity, we titrated C8-BID and hex with recombinant BAX (Figure 4E). Titration of hex or C8-BID with BAX did not promote 6A7 IP, but the combined treatment of C8-BID, hex, and BAX promoted dose-dependent 6A7 positivity (Figure 4E).

BAX, BID, and hex cooperation was examined using a large unilamellar vesicles (LUV) model system that faithfully measures BAX activation (Kuwana et al., 2002). LUVs containing 7% cardiolipin (CL) are generally used to promote BAX and C8-BID synergy and permeabilization, but CL is not highly represented at the OMM. Therefore, CL-free LUVs were examined for BAX function by combining them with C8-BID and titrating hex (Figure 4F). BAX, N/C-BID, and hex separately did not promote LUV permeabilization, and the combined treatment of BAX and N/C-BID resulted in only minimal release (Figure 4F). BAX and N/C-BID combined with hex caused dose-dependent permeabilization of the

LUVs suggesting BAX, N/C-BID, and hex cooperation in BAX-mediated membrane permeabilization (Figure 4F). Importantly, the exogenous addition of ceramide, SPH, or S1P did not promote BAX activation to similar degrees as hex (Figures S4A and S4B). For additional control and comparison, we generated LUVs where the 7% CL was replaced with ceramide, SPH, or S1P, but none of these LUVs promoted efficient BAX activation compared to hex (Figure S4C). Together, these data suggest that hex can directly regulate BAX and BID function to promote MOMP.

One alternative explanation for S1P regulation of C8-BID induced, BAK-dependent cyto *c* release could be that sphingolipid metabolism induces transient openings of the mitochondrial permeability transition pore (MPTP) impacting on sensitivity to MOMP (Scorrano et al., 2002). To test this, we determined if S1P regulation of C8-BID induced, BAK-dependent cyto *c* release was sensitive to cyclosporine A (CsA), an inhibitor of MPTP. As shown in Figure 4G, S1P and C8-BID promoted BAK-dependent cyto *c* release that was insensitive to CsA, suggesting the MPTP was not involved.

Hexadecenal Binds and Promotes BAX Activation

We noted that mid-range μM concentrations of hex directly promoted BAX activation akin to detergent treatment (Figures S4A and S4B). We took advantage of this observation to better understand the functional relationship between BAX and hex. Sphingolipid metabolites ranging from SM to hex were examined for their ability to directly induce BAX activation as measured by oligomerization (Figure 5A). BAX was treated with SM, C16, SPH, S1P, OPEA, or hex in the presence of BMH before analyzing oligomerization. All doses of hex promoted BAX oligomerization, whereas S1P promoted only weak BAX activation (Figure 5A). Octylglucoside (OG) and CHAPS were positive and negative controls in the assay, respectively. To determine if the BAX oligomers in Figure 5A could induce MOMP, the sphingolipid or detergent treated BAX samples were extensively dialyzed after treatment and added to $bak^{-/-}bax^{-/-}$ mitochondria. Indeed, hex-activated BAX induced MOMP and cyto *c* release (Figure 5B).

The ability of hex to directly promote BAX oligomerization suggests that BAX and hex physically associate. To determine the specificity of this association, we analyzed the binding of BAX to commercially available sphingolipid arrays (Figures S5A and S5B). BAX was incubated with the sphingolipid arrays according to the manufacturer's protocol, but we observed no detectable binding between BAX and the lipids tested. We therefore compared the binding of BAX to S1P and hex with a chloroform-spotted array using the same detection methods and observed a dose-dependent, BAX-hex association (Figure S5C and Figures 5C and 5D). The same assay was repeated comparing BAX and BCL-xL for hex binding, and while BAX bound to hex, a BCL-xL-hex interaction was not observed, suggesting that the binding of hex to the BAX protein is specific (Figure 5D). An immunoprecipitating antibody against BAX or BCL-xL was spotted onto the arrays as a positive control for the protein capture and detection conditions (Figure 5D). To probe the specificity of the hex-BAX association, hex and a closely related compound, hexadecanal, were titrated in the presence of BAX and BMH before analyzing BAX oligomerization (Figure 5E). Hex induced dose-dependent BAX oligomerization, whereas hexadecanal did not, suggesting that not all long chain aldehydes have the ability to induce BAX activation.

Sphingolipid Metabolism Regulates Sensitivity to Apoptosis and Clonogenic Survival

We tested whether the sphingolipid pathway regulates mitochondrial sensitivity to BAK and BAX activation and MOMP in a cellular context by observing the effect of enhancing or inhibiting sphingolipid metabolism. As a cellular model for death receptor-mediated, BID-dependent apoptosis, HeLa cells were titrated with different doses of TNF in the presence of

cyclohexamide (CHX) and analyzed 8h later to determine an appropriate TNF concentration for further study. HeLa cells did not respond to TNF or CHX treatment alone; but they underwent dose-dependent apoptosis with TNF in the presence of CHX (Figure 6A). In a parallel experiment, we transiently transfected empty vector, SMPD3, or SMPD4. The exogenous expression of SMPD3 or SMPD4 enhanced the basal level of apoptosis, but not markedly, and the response 24 hr posttransfection did not increase when analyzed 48 and 72 hr posttransfection (Figure 6A and data not shown). We then examined the effect of exogenous SMPD3 or SMPD4 expression on TNF-induced apoptosis. We observed that the exogenous expression of SMPD3 or SMPD4 greatly enhanced sensitivity to TNF-induced apoptosis in a dose-dependent manner, whereas expression of the vector alone did not influence survival (Figure 6B).

As BH3-only proteins are essential to the induction of MOMP, we tested if SMPD3 cooperated with exogenous BH3-only protein expression to promote apoptosis. We chose to evaluate three BH3-only proteins: BIM-S and tBID, two well-defined direct activator BH3-only proteins and potent inducers of apoptosis; and BAD, a de-repressor BH3-only protein that is not a strong inducer of apoptosis (Kuwana et al., 2005; Letai et al., 2002). WT mouse embryonic fibroblasts (MEFs) were transiently transfected with either empty vector or SMPD3 in the presence of increasing masses of BIM-S, BAD, or tBID cDNA and analyzed 24 hr later. As shown in Figure S6A, BIM-S and tBID expression demonstrated dose-dependent induction of apoptosis, and this was enhanced by SMPD3 expression. BAD expression alone did not induce marked apoptosis, as expected, but there was an observable cooperation between BAD and SMPD3. To ensure that these observations were due to the enzymatic activity of SMPD3, we tested two SMPD3 catalytic mutants (SMPD3^{D428A} and SMPD3^{H639A}) for synergy with BIM-S (Milhas et al., 2010). While WT SMPD3 synergized with BIM-S in a dose-dependent manner, both SMPD3 mutants failed to synergize with BIM-S to promote apoptosis (Figure S6B). We probed BCL-2 family expression following SMPD3 and SMPD4 transient expression to ensure that the enhanced apoptosis was not due to changes in pro- or antiapoptotic protein expression (Figure S6C).

Our study suggests that a SPH kinase activity is required upstream of both BAK- and BAX-dependent MOMP. To examine this requirement in cells, we used WT MEFs in which *sphk1* or *sphk2* was silenced by RNAi and tested their sensitivity to TNF-induced apoptosis. Lysates from the *sphk1* and *sphk2* knockdown cells were confirmed for downregulation of SPHK1 and SPHK2 protein (Figure 6C). Control, *sphk1*, and *sphk2* RNAi cell lines were then treated with CHX and TNF, cultured for 6 hr, and analyzed by flow cytometry (Figure 6D). Control and *sphk1* RNAi cells were sensitive to TNF-induced apoptosis; however, the loss of *sphk2* expression resulted in resistance to apoptosis (Figure 6D). Silencing of *sphk2* in MEFs also resulted in marked resistance to the ActD induced apoptosis (Figure S6D). Reduction in apoptosis was not due to changes in BCL-2 family expression following *sphk2* knockdown (Figure S6E).

As loss of *sphk2* expression correlated with reduced apoptosis and our previous data demonstrate that changes in S1P regulate mitochondrial sensitivity to MOMP, we evaluated the subcellular localization of SPHK2. While the HM fraction contained both SPHK1 and SPHK2, the majority of SPHK1 and SPHK2 were localized to the mS and mitochondria, respectively. The purity of the fractions was confirmed by localization of PDI and cyto *c* (Figure 6E). SPHK2 activity was also analyzed by an enzymatic assay specific to SPHK2 comparing μS and mitochondria; and this confirmed that mitochondria contain functional SPHK2 (Figures S6F and S6G). We also compared the endogenous mitochondrial SPHK2 activity against recombinant SPHK2 to ensure specificity within our assay (Figures S6F and S6G).

To directly test the role of SPHK2 in regulating sensitivity to C8-BID, we analyzed the influence of SPHK2 (Figures S6F and S6G) on mediating C8-BID induced, BAK activation, and MOMP. WT HM fractions were treated with C8-BID in the presence or absence of SPHK2. Neither C8-BID at 5 or 25 pM, nor SPHK2 independently promoted MOMP, but when combined, C8-BID and SPHK2 induced complete cyto *c* release that was inhibited by BCL-xL (Figure 6F, lower panels). Using traditional MOMP conditions, our pharmacological inhibitor data in Figures 3C and 3H demonstrate that a SPH kinase is active, suggesting that this enzyme has access to a residual ATP pool within the HM fraction. As we are adding SPHK2 to the reactions and the accessibility of the ATP pool was unknown, we provided a means of ATP production. We compared MOMP reactions using mitochondrial assay buffer (MAB, typical buffer used in MOMP assays, no additional ATP source, upper panels), and respiration buffer (RB, supplemented with mitochondrial complex substrates and ADP to generate ATP, lower panels), and observed that the effect of SPHK2 indeed required an ATP source (Figure 6F, compare upper and lower panels). Additionally, we examined recombinant SPHK1 plus C8-BID and also observed a MOMP-promoting activity, albeit less than with SPHK2, suggesting that the mitochondrial localization of SPHK2 likely promotes MOMP (Figure 6F).

We next tested several pharmacological regulators of the sphingolipid pathway to determine their influence on cellular apoptosis and clonogenic survival. HeLa cells were treated with all the previous inhibitors of sphingolipid metabolism; however, only D609, GW4869, DMS, SKI, DOP, and THI permitted further analysis as the other drugs (FB1, MAPP, and NOE) were toxic at the doses and/or treatment times required for the survival assays (Figure S7A, and data not shown). HeLa cells were pretreated with D609, GW4869, DMS, SKI, DOP, and THI for 6 h; proapoptotic stimulation was added, cells were cultured for 24 hr, and analyzed. D609, GW4869, DMS, SKI, DOP, and THI each afforded protection from the three proapoptotic stimuli, suggesting that pharmacologically targeting the sphingolipid metabolic pathway at various stages can directly impact on cellular survival (Figures S7B-D). Moreover, the clonogenic potential of these cells was also assayed; however, DMS and SKI were toxic in this assay and could not be evaluated (data not shown). As in Figures S7B–S7D, HeLa cells were pretreated with D609, GW4869, DOP, and THI, proapoptotic stimulation was added and maintained for 12 hr, then cultured for two weeks prior to staining with methylene blue. Inhibition of N-SMase activity or the S1P lyase activity resulted in observable clonogenic survival despite apoptosis signaling through the extrinsic or intrinsic pathways (Figures 7A–7D). As a control for the loss of S1P lyase function, which could result in enhanced extracellular S1P signaling, a S1P treatment group was also included, but this did not result in enhanced clonogenic survival (Pyne et al., 2009).

DISCUSSION

Prior to the elucidation of caspase-activation mechanisms, a prominent notion held that SM hydrolysis and subsequent ceramide formation had a direct fundamental role in engaging cell death (Obeid et al., 1993); yet molecular mechanisms whereby ceramide initiates and executes apoptosis have been scant (Bartke and Hannun, 2009). A direct role for ceramide in mitochondrial integrity has been proposed (Siskind et al., 2002, 2006), but our studies suggest an alternative mechanistic view, such that ceramide is a precursor of two molecules, S1P and hex, which facilitate BAK/BAX activation leading to MOMP.

We propose that ceramide is produced by the constitutive hydrolysis of SM by a N-SMase in a mitochondria-associated compartment. Ceramide is then transferred to mitochondria, where enzymes further convert ceramide to produce S1P and hex. Indeed, evidence exists that N-SMases are associated with the heavy and light membrane fractions, and ceramide transport between organelles is described (Hanada et al., 2009; Sawai et al., 2000; Stiban et

al., 2008; Wu et al., 2010; Yabu et al., 2009). Upon purification of mitochondria from the HM fraction, sensitivity to C8-BID induced BAK/BAX activation rapidly wanes unless components of the sphingolipid pathway are provided or metabolism is inhibited. We propose that mitochondria may regulate their sphingolipid composition through both forward (ceramide - SPH - S1P) and reverse pathways (S1P - SPH - ceramide).

SM hydrolysis and subsequent changes in sphingolipid profiles are associated with enhanced sensitivity to proapoptotic stimulation. In breast cancer cells, a bSMase targeted to mitochondria was shown to promote apoptosis, and it was suggested that mitochondrial SM hydrolysis enhanced BAX mitochondrial translocation (Birbes et al., 2001, 2005). Proapoptotic stimuli promote SM hydrolysis and marked alterations to the intracellular sphingolipid profile, perhaps to establish the appropriate milieu at the OMM to promote BAK/BAX function. For instance, TNF specifically induces SMPD3 function in MCF-7 cells to promote SM hydrolysis to ceramide (Clarke et al., 2011). Indeed, ceramide has been suggested to directly regulate the permeabilization function of BAX using isolated mitochondria and phospholipid membranes; and a recent report suggests that mitochondrial macrodomains rich in ceramide promote BAX activity (Ganesan et al., 2010; Lee et al., 2011). In support of this hypothesis, reversing sphingolipid metabolism to favor SM accumulation decreased sensitivity to BAX-mediated death (Yang et al., 2006).

Earlier observations suggested that CL is required for MOMP, however the presence of this lipid in the OMM is controversial (Kuwana et al., 2002; Lutter et al., 2000; Ott et al., 2009). Our studies suggest that mitochondria interact with distinct cellular components to establish the sphingolipid milieu that is compatible with MOMP. Indeed, we have found that lipid vesicles lacking CL can be permeabilized by the combination of BID and BAX, provided hex is present. Several proteins (e.g., DRP-1, MTCH2, OPA-1, and TOM22) are also implicated in orchestrating MOMP, by coordinating BAX and/or BID function at the OMM or by directly regulating the mitochondrial network, and it will be necessary to determine how S1P and hex potentially cooperate with the above proteins to fully appreciate the mechanisms that control BAK and BAX activation (Bellot et al., 2007; Cassidy-Stone et al., 2008; Montessuit et al., 2010; Yamaguchi et al., 2008; Zaltsman et al., 2010). Structural and biochemical studies suggest that BAK/BAX activation involves a displacement of helix a1, leading to distal exposure of the BH3 region of these molecules (Dewson et al., 2008; Gavathiotis et al., 2008). The binding of S1P to BAK, or hex to BAX, may act to lower the thermodynamic constraints on these conformational changes. In support of this idea, we found that BID-induced exposure the 6A7 epitope on BAX is facilitated by hex, which directly binds to BAX.

TNF- and UV-induced apoptosis are reported to signal through N-SMase-regulated pathways (Clarke et al., 2011; Dai et al., 2004; Luberto et al., 2002). We also observed that several such inhibitors act to preserve cell survival following treatments that normally induce apoptosis. These observations support the idea that downstream components of the pathway, such as S1P and hex, promote MOMP and cell death. Our finding that S1P lyase inhibitors supported cell survival (where potentially BAK activation, facilitated by S1P could still occur) is consistent with the protective effects of *bax* deletion in cells (Zhang et al., 2000). Interestingly, S1P lyase deficiency is described to promote DNA damage resistance and enhanced tumor xenograft formation (Colie et al., 2009; Oskouian et al., 2006). The expression of S1P lyase is also reduced in colon cancer cells, which are suggested to primarily utilize BAX to promote apoptosis highlighting the potential cooperation between BAX and SPH lyase function and its products (Oskouian et al., 2006).

Ceramide production can occur in cells independently of the N-SMases, such as by acidic SMase or ceramide synthase, both of which can be activated by stress conditions (Kolesnick

and Fuks, 2003; Santana et al., 1996). Increased ceramide production by these mechanisms may contribute to MOMP by providing precursors at the OMM. S1P lyase appears to directly impact on cellular survival following DNA damage, and studies suggest that hex coordinates apoptosis through BID, BIM, and BAX (Kumar et al., 2011a; Kumar et al., 2011b). Finally, SMPD3 is lost or mutated in a subset of human lymphomas (Kim et al., 2008), and the *SMPD3* promoter is shown to be hyper-methylated in aggressive breast tumors (Demircan et al., 2009). It is tempting to speculate that such changes can facilitate cell survival by restricting MOMP through the mechanisms we describe.

EXPERIMENTAL PROCEDURES

Heavy Membrane Fractions, Mitochondrial Purification, and Cyto-c Release Assay

Heavy membrane fractions were purified from murine liver using dounce homogenization and differential centrifugation in mitochondrial isolation buffer. To purify mitochondria from the HM fraction, the HM fraction was prepared in the absence of BSA, and 1 μg/mg of proteomics grade trypsin was added and incubated on ice for 10 min. Soybean trypsin inhibitor (10 mg/mg trypsin) was added, incubated on ice for 30 min, and the trypsinized fraction was loaded on top of a 26%/60% Percoll gradient. Mitochondria at the 26%/60% Percoll interface were removed with an 18 gauge syringe, and washed twice in MIB. For MOMP assays, HM fractions or mitochondria were incubated in MIB supplemented to 110 mM KCl (mitochondrial assay buffer, MAB), plus or minus proteins and lipids for 1 hr at 37°C. Reactions were then centrifuged at $5,500 \times g$ for 10 min, the resulting pellets and supernatants were analyzed for cyto c by SDS-PAGE and western blot. For high throughput, total cyto c was occasionally determined by a sample containing mitochondria solubilized in 1% CHAPS instead of analyzing the pellet fractions.

Acidic and N-SMase Assay

For acidic SMase (asm) analysis, samples were prepared in 0.2 M sodium acetate pH 5.0 and 0.1% Triton X-100. For N-SMase analysis, samples were prepared in 25 mM Tris-HCl (pH 7.4), 5 mM EDTA and 0.2% Triton X-100. Samples were incubated for 30 min at 37°C, subjected to Folch extraction and the amount of choline-methyl-^{14}C release was measured by scintillation counting.

Survival Assays

HeLa cells and MEFs were transfected, then treated with TNF and CHX, cultured for 24 hr, harvested by trypsinization, stained with AnnexinV and analyzed by flow cytometry. For pharmacological inhibitor studies, HeLa cells were pretreated with indicated pharmacological inhibitors of the SM pathway for 6 hr before apoptotic inducers (anti-Fas/CD95 antibody TNF or ActD) were added. For clonogenic survival studies, HeLa cells were pretreated with indicated pharmacological inhibitors of the SM pathway for 6 hr, apoptotic inducers added, and cells cultured for 12 hr before changing the media. Colonies were stained with methylene blue 12 days after treatment.

Please see the online Extended Experimental Procedures for more details.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

REFERENCES

Alphonse G, Bionda C, Aloy MT, Ardail D, Rousson R, Rodriguez-Lafrasse C. Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene. 2004; 23:2703–2715. [PubMed: 15048093]

Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J. Lipid Res. Suppl. 2009; 50:S91–S96.

Bellot G, Cartron PF, Er E, Oliver L, Juin P, Armstrong LC, Bornstein P, Mihara K, Manon S, Vallette FM. TOM22, a core component of the mitochondria outer membrane protein translocation pore, is a mitochondrial receptor for the proapoptotic protein Bax. Cell Death Differ. 2007; 14:785–794. [PubMed: 17096026]

Birbes H, El Bawab S, Hannun YA, Obeid LM. Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis. FASEB J. 2001; 15:2669–2679. [PubMed: 11726543]

Birbes H, Luberto C, Hsu YT, El Bawab S, Hannun YA, Obeid LM. A mitochondrial pool of sphingomyelin is involved in TNFalpha-induced Bax translocation to mitochondria. Biochem. J. 2005; 386:445–451. [PubMed: 15516208]

Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, Kurth MJ, Shaw JT, Hinshaw JE, Green DR, et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer-membrane permeabilization. Dev. Cell. 2008; 14:193–204. [PubMed: 18267088]

Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, Green DR. Mechanism of apoptosis induction by inhibition of the antiapoptotic BCL-2 proteins. Proc. Natl. Acad. Sci. USA. 2008; 105:20327–20332. [PubMed: 19074266]

Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol. Cell. 2010; 37:299–310. [PubMed: 20159550]

Clarke CJ, Cloessner EA, Roddy PL, Hannun YA. Neutral sphingomyelinase 2 (nSMase2) is the primary neutral sphingomyelinase isoform activated by tumour necrosis factor-alpha in MCF-7 cells. Biochem. J. 2011; 435:381–390. [PubMed: 21303347]

Colie S, Van Veldhoven PP, Kedjouar B, Bedia C, Albinet V, Sorli SC, Garcia V, Djavaheri-Mergny M, Bauvy C, Codogno P, et al. Disruption of sphingosine 1-phosphate lyase confers resistance to chemotherapy and promotes oncogenesis through Bcl-2/Bcl-xL upregulation. Cancer Res. 2009; 69:9346–9353. [PubMed: 19934311]

Csordas G, Renken C, Varnai P, Walter L, Weaver D, Buttle KF, Balla T, Mannella CA, Hajnoczky G. Structural and functional features and significance of the physical linkage between ER and mitochondria. J. Cell Biol. 2006; 174:915–921. [PubMed: 16982799]

Dai Q, Liu J, Chen J, Durrant D, McIntyre TM, Lee RM. Mitochondrial ceramide increases in UV-irradiated HeLa cells and is mainly derived from hydrolysis of sphingomyelin. Oncogene. 2004; 23:3650–3658. [PubMed: 15077187]

de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature. 2008; 456:605–610. [PubMed: 19052620]

Demircan B, Dyer LM, Gerace M, Lobenhofer EK, Robertson KD, Brown KD. Comparative epigenomics of human and mouse mammary tumors. Genes Chromosomes Cancer. 2009; 48:83–97. [PubMed: 18836996]

Deng X, Yin X, Allan R, Lu DD, Maurer CW, Haimovitz-Friedman A, Fuks Z, Shaham S, Kolesnick R. Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of C. elegans. Science. 2008; 322:110–115. [PubMed: 18832646]

Dewson G, Kratina T, Sim HW, Puthalakath H, Adams JM, Colman PM, Kluck RM. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. Mol. Cell. 2008; 30:369–380. [PubMed: 18471982]

Ganesan V, Perera MN, Colombini D, Datskovskiy D, Chadha K, Colombini M. Ceramide and activated Bax act synergistically to permeabilize the mitochondrial outer membrane. Apoptosis. 2010; 15:553–562. [PubMed: 20101465]

Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, Tu HC, Kim H, Cheng EH, Tjandra N, et al. BAX activation is initiated at a novel interaction site. Nature. 2008; 455:1076–1081. [PubMed: 18948948]

Hanada K, Kumagai K, Tomishige N, Yamaji T. CERT-mediated trafficking of ceramide. Biochim. Biophys. Acta. 2009; 1791:684–691. [PubMed: 19416656]

Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 2008; 9:139–150. [PubMed: 18216770]

Hayashi T, Rizzuto R, Hajnoczky G, Su TP. MAM: more than just a housekeeper. Trends Cell Biol. 2009; 19:81–88. [PubMed: 19144519]

Hsu YT, Youle RJ. Nonionic detergents induce dimerization among members of the Bcl-2 family. J. Biol. Chem. 1997; 272:13829–13834. [PubMed: 9153240]

Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, et al. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 2008; 111:4716–4722. [PubMed: 18299447]

Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene. 2003; 22:5897–5906. [PubMed: 12947396]

Kumar A, Byun HS, Bittman R, Saba JD. The sphingolipid degradation product trans-2-hexadecenal induces cytoskeletal reorganization and apoptosis in a JNK-dependent manner. Cell. Signal. 2011a; 23:1144–1152. [PubMed: 21385609]

Kumar A, Oskouian B, Fyrst H, Zhang M, Paris F, Saba JD. S1P lyase regulates DNA damage responses through a novel sphingolipid feedback mechanism. Cell Death Dis. 2011b; 2:e119. [PubMed: 21368890]

Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, Newmeyer DD. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell. 2005; 17:525–535. [PubMed: 15721256]

Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, Green DR, Newmeyer DD. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell. 2002; 111:331–342. [PubMed: 12419244]

Lee H, Rotolo JA, Mesicek J, Penate-Medina T, Rimner A, Liao WC, Yin X, Ragupathi G, Ehleiter D, Gulbins E, et al. Mitochondrial Ceramide-Rich Macrodomains Functionalize Bax upon Irradiation. PLoS ONE. 2011; 6:e19783. [PubMed: 21695182]

Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate Mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002; 2:183–192. [PubMed: 12242151]

Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, Waymire KG, Mahar P, Frauwirth K, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell. 2000; 6:1389–1399. [PubMed: 11163212]

Liu YY, Han TY, Yu JY, Bitterman A, Le A, Giuliano AE, Cabot MC. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J. Lipid Res. 2004; 45:933–940. [PubMed: 14967819]

Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM, Hannun YA, Smith GK. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J. Biol. Chem. 2002; 277:41128–41139. [PubMed: 12154098]

Lutter M, Fang M, Luo X, Nishijima M, Xie X, Wang X. Cardiolipin provides specificity for targeting of tBid to mitochondria. Nat. Cell Biol. 2000; 2:754–761. [PubMed: 11025668]

Mesicek J, Lee H, Feldman T, Jiang X, Skobeleva A, Berdyshev EV, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell. Signal. 2010; 22:1300–1307. [PubMed: 20406683]

Milhas D, Clarke CJ, Idkowiak-Baldys J, Canals D, Hannun YA. Anterograde and retrograde transport of neutral sphingomyelinase-2 between the Golgi and the plasma membrane. Biochim. Biophys. Acta. 2010; 1801:1361–1374. [PubMed: 20713176]

Montessuit S, Somasekharan SP, Terrones O, Lucken-Ardjomande S, Herzig S, Schwarzenbacher R, Manstein DJ, Bossy-Wetzel E, Basanez G, Meda P, et al. Membrane remodeling induced by the dynamin-related protein Drp1 stimulates Bax oligomerization. Cell. 2010; 142:889–901. [PubMed: 20850011]

Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science. 1993; 259:1769–1771. [PubMed: 8456305]

Oskouian B, Sooriyakumaran P, Borowsky AD, Crans A, Dillard-Telm L, Tam YY, Bandhuvula P, Saba JD. Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer. Proc. Natl. Acad. Sci. USA. 2006; 103:17384–17389. [PubMed: 17090686]

Ott M, Norberg E, Zhivotovsky B, Orrenius S. Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death Differ. 2009; 16:1075–1082. [PubMed: 19521421]

Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B, et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005; 65:11667–11675. [PubMed: 16357178]

Pyne NJ, Long JS, Lee SC, Loveridge C, Gillies L, Pyne S. New aspects of sphingosine 1-phosphate signaling in mammalian cells. Adv. Enzyme Regul. 2009; 49:214–221. [PubMed: 19534035]

Rodriguez-Lafrasse C, Alphonse G, Aloy MT, Ardail D, Gerard JP, Louisot P, Rousson R. Increasing endogenous ceramide using inhibitors of sphingolipid metabolism maximizes ionizing radiation-induced mitochondrial injury and apoptotic cell killing. Int. J. Cancer. 2002; 101:589–598. [PubMed: 12237902]

Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M, Cordon-Cardo C, Schuchman EH, Fuks Z, Kolesnick R. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 1996; 86:189–199. [PubMed: 8706124]

Sawai H, Okamoto Y, Luberto C, Mao C, Bielawska A, Domae N, Hannun YA. Identification of ISC1 (YER019w) as inositol phosphosphingolipid phospholipase *c* in Saccharomyces cerevisiae. J. Biol. Chem. 2000; 275:39793–39798. [PubMed: 11006294]

Scorrano L, Ashiya M, Buttle K, Weiler S, Oakes SA, Mannella CA, Korsmeyer SJ. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome *c* during apoptosis. Dev. Cell. 2002; 2:55–67. [PubMed: 11782314]

Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, Korsmeyer SJ. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science. 2003; 300:135–139. [PubMed: 12624178]

Siskind LJ, Kolesnick RN, Colombini M. Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins. J. Biol. Chem. 2002; 277:26796–26803. [PubMed: 12006562]

Siskind LJ, Kolesnick RN, Colombini M. Ceramide forms channels in mitochondrial outer membranes at physiologically relevant concentrations. Mitochondrion. 2006; 6:118–125. [PubMed: 16713754]

Stiban J, Caputo L, Colombini M. Ceramide synthesis in the endoplasmic reticulum can permeabilize mitochondria to proapoptotic proteins. J. Lipid Res. 2008; 49:625–634. [PubMed: 18073406]

Taha TA, Kitatani K, El-Alwani M, Bielawski J, Hannun YA, Obeid LM. Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J. 2006a; 20:482–484. [PubMed: 16507765]

Taha TA, Mullen TD, Obeid LM. A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim. Biophys. Acta. 2006b; 1758:2027–2036. [PubMed: 17161984]

Wagner T, Rafael J. Biochemical properties of liver megamitochondria induced by chloramphenicol or cuprizone. Exp. Cell Res. 1977; 107:1–13. [PubMed: 193704]

Walter L, Hajnoczky G. Mitochondria and endoplasmic reticulum: the lethal interorganelle cross-talk. J. Bioenerg. Biomembr. 2005; 37:191–206. [PubMed: 16167176]

Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, Korsmeyer SJ. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000; 14:2060–2071. [PubMed: 10950869]

Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001; 292:727–730. [PubMed: 11326099]

Wu BX, Rajagopalan V, Roddy PL, Clarke CJ, Hannun YA. Identification and characterization of murine mitochondria-associated neutral sphingomyelinase (MA-nSMase), the mammalian sphingomyelin phosphodiesterase 5. J. Biol. Chem. 2010; 285:17993–18002. [PubMed: 20378533]

Yabu T, Shimuzu A, Yamashita M. A novel mitochondrial sphingomyelinase in zebrafish cells. J. Biol. Chem. 2009; 284:20349–20363. [PubMed: 19429680]

Yamaguchi R, Lartigue L, Perkins G, Scott RT, Dixit A, Kushnareva Y, Kuwana T, Ellisman MH, Newmeyer DD. Opa1-mediated cristae opening is Bax/Bak and BH3 dependent, required for apoptosis, and independent of Bak oligomerization. Mol. Cell. 2008; 31:557–569. [PubMed: 18691924]

Yang Z, Khoury C, Jean-Baptiste G, Greenwood MT. Identification of mouse sphingomyelin synthase 1 as a suppressor of Bax-mediated cell death in yeast. FEMS Yeast Res. 2006; 6:751–762. [PubMed: 16879426]

Zaltsman Y, Shachnai L, Yivgi-Ohana N, Schwarz M, Maryanovich M, Houtkooper RH, Vaz FM, De Leonardis F, Fiermonte G, Palmieri F, et al. MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria. Nat. Cell Biol. 2010; 12:553–562. [PubMed: 20436477]

Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 2000; 290:989–992. [PubMed: 11062132]

Figure 1. Microsomes Restore Mitochondrial Sensitivity to Direct Activator Stimulation
(A) HM and mitochondria were treated with C8-BID (0.5, 1, and 5 nM).
(B) The HM fraction was isolated, and the μS and mitochondrial (Mito) fractions were purified. All three fractions were subjected to western blot. In parallel, each fraction was incubated with 10 nM C8-BID for 1 hr at 37°C, washed, and subjected to western blot.
(C) Same as in (A), but treatments included BID BH3 and BIM BH3 (1, 5, and 20 μM).
(D) HM (50 μg) and mitochondria (50 μg) were treated as indicated (C8-BID, 1 nM; BID BH3, 5 μM; BCL-xL, 500 nM; μS, 5, 25, and 50 μg).
(E) HM, mitochondrial, and μS fractions were subjected to western blot.
(F) HM, mitochondrial, and μS fractions were treated with limited proteolysis, lysed, and subjected to western blot.
(G) Purification scheme to identify SMPD3 and SMPD4.
See also Figure S1.

Figure 2. A Neutral SMase Activity Cooperates within the BCL-2 Family to Promote MOMP

(A) SMPD2-4 IVTT with ^{35}S-Met were subjected to SDS-PAGE. Lines denoting 2, 3, and 4 indicate full-length products.

(B) Nonradioactive IVTT reactions were performed and subjected to ^{14}C-SM hydrolysis ± 10 µM GW4869.

(C) Nonradioactive IVTT reactions were performed and combined with WT HM fractions. C8-BID (1 nM for control; 0.05 nM for IVTT combinations); GW4869 (25 µM) and BCL-xL (50 nM).

(D) WT HM fractions were pretreated with FB1 (1, 5, 10, and 25 µM), bSMase (0.0001, 0.0005, 0.0010, and 0.0025U) or D609 (1, 5, and 25 µM) for 1 hr at 37°C before the addition of 0.05 nM C8-BID.

(E) Liver homogenate, solubilized HM fraction, or solubilized mitochondria (1 µg) were subjected to ^{14}C-SM hydrolysis.

(F) HM fraction was subjected to limited proteolysis (0, 1, 2, 5, 10, and 20 min) on ice, and fractionated into pellet (mitochondria) and supernatant (contains released µS) before ^{14}C-SM hydrolysis and western blot.

(G) WT HM fractions were combined with C8-BID (0.05, 0.1, 0.5, and 1 nM) or as indicated in the presence of SMPD3 (1, 5, and 20 ng) and BCL-xL (500 nM).

(H) *bak*$^{-/-}$*bax*$^{-/-}$ HM fractions treated with SMPD3 (20 ng; or 1, 20 ng), BAX (25 nM), C8-BID (10 nM; or 1, 10 nM; or as indicated), and BCL-xL (500 nM).

(I) SMPD3 was tested for ^{14}C-SM hydrolysis and compared to bSMase. All data are reported as ± SD.

See also Figure S2.

Figure 3. Inhibition of the Sphingolipid Pathway Blocks MOMP

(A) Substrates, products, and enzymes, together with enzyme inhibitors tested.

(B–D) WT HM fractions were pretreated with the indicated drugs for 1 hr at 37°C prior to addition of C8-BID (1 nM). GW4869 (2, 10, and 20 μM), MAPP (2, 10, and 20 μM), NOE (0.1, 0.5, and 1 μM), DMS (2.5, 12.5, and 25 μM), SKI (5, 25, and 50 μM), DOP (1, 5, and 10 μM), THI (1, 5, and 10 μM).

(E) HM and subsequent mitochondria were purified in the presence of DOP/THI (10 μM each) before treatment with C8-BID (0, 0.5, and 1 nM).

(F) The levels of S1P were measured following isolation as in (E).

(G and H) $bak^{-/-}bax^{-/-}$ HM fractions were pretreated with drugs (two higher doses from above) for 1 hr at 37°C prior to addition of BAX (25 nM) and C8-BID (10 nM).

(I) The HM fraction was pretreated with the highest dose of the inhibitors listed in (B)–(D) for 1 hr at 37°C, prior to addition of BAX (25 nM) and C8-BID (10 nM). Reactions were then incubated for 1 hr at 37°C before lysis in 1% CHAPS buffer and IP. A MOMP reaction lysed in 1% Triton X-100 is the positive control. All graphed data are reported as ± SD. See also Figure S3.

Figure 4. Reconstitution of the Sphingolipid Pathway Replaces the Heterotypic Membrane Requirement for MOMP

(A) Purified mitochondria were preincubated for 1 hr with indicated sphingolipids (SM or C16, 1 μM), purified sphingolipid enzymes (bSMase or ASAH2, 0.001 U/μl) or drugs (GW4869 or MAPP, 25 μM) before the addition of C8-BID (1 nM). SPH was added at 0.1 or 1 μM.

(B) WT mitochondria were incubated with indicated sphingolipids (0.1, 0.5, and 1 μM) prior to the addition of C8-BID (1 nM). As a positive control, purified μS (50 μg) was also tested for sensitization.

(C) *bak⁻/⁻ bax⁻/⁻* mitochondria were treated with indicated sphingolipids (1 μM).

(D) *bak⁻/⁻ bax⁻/⁻* HM fractions and mitochondria were pretreated with BAX (25 nM), C8-BID (10 nM), and indicated sphingolipids (0.1 and 1 μM).

(E) BAX was incubated with hex (0.1, 0.5, and 1 μM) and C8-BID (5, 10, and 25 nM) for 1 hr at 37°C before IP with anti-BAX 6A7. Triton X-100 (0.5%) was added as a positive control for detergent-treatment activation.

(F) LUVs (PC, PE, PI, PS, no CL) were treated with indicated proteins and hex.

(G) Mitochondria were pretreated with CsA (100 nM) for 1 hr at 37°C prior to the addition of S1P (0.1, 0.5, and 1 μM) and C8-BID (1 nM). All data are reported as ± SD.

See also Figure S4.

Figure 5. Hexadecenal Binds and Promotes BAX Activation
(A) BAX (10 nM) was incubated with indicated lipids or detergents (0.1 and 1 mM) in the presence of BMH (100 nM) for 1 hr at 37°C before western blot.

(B) As in (A), but instead of oligomerization analysis, samples were extensively dialyzed, combined with *bak*[-/-]*bax*[-/-] HM, and incubated for 1 hr at 37°C before fractionation, and western blot for cyto c.

(C and D) Nitrocellulose membranes spotted with indicated picomoles of S1P or hex (combined with BSA and ponceau red for visualization) were incubated with either 50 ng of BCL-xL or BAX and probed with anti-BCL-xL or anti-BAX (horizontal mark for anti-BCL-xL, vertical for anti-BAX). The positive controls (*) on the blots are spots containing an IP antibody for BCL-xL or BAX.

(E) BAX (10 nM) was incubated with hexadecanal or hex (0, 0.1, 1, 5, and 10 μM) in the presence of BMH (100 nM) for 1 hr at 37°C.

See also Figure S5.

Figure 6. SMPD3 and SMPD4 Regulate Sensitivity to Apoptosis, and a Mitochondrial Sphingosine Kinase Activity Sensitizes for MOMP

(A) HeLa cells were transfected with vector, SMPD3, or SMPD4; or treated with CHX (10 μg/ml), TNF (25 ng/ml; or 5, 10, 15, 20, and 25 ng/ml); cultured for 24 hr and stained with Annexin V-PE.

(B) HeLa cells were transfected with 100, 500, 1000 ng of vector, SMPD3 or SMPD4, cultured for 24 hr, treated with CHX (10 μg/ml) and TNF (15 ng/ml), cultured for 6 hr and stained with Annexin V-PE.

(C) WT MEFs retrovirally infected to silence *sphk1* or *sphk2* were analyzed by western blot.

(D) Control, *sphk1*, and *sphk2* RNAi cell lines were treated with CHX (5 μg/ml) and TNF (10 ng/ml), cultured for 6 hr, and stained with Annexin V-PE.

(E) HM fraction, mitochondria, and μS were subjected to western blot.

(F) WT HM fractions were treated with C8-BID (5, 25, 1000* pM, *positive control), SPHK1 (25 ng), SPHK2 (25 ng), BCL-xL (50 nM) in MAB or RB.

See also Figure S6.

Figure 7. The SMase Pathway Regulates Sensitivity to Apoptosis
(A) HeLa cells were pretreated with indicated pharmacological inhibitors for 6 hr, apoptotic inducers (CH11/CHX, 0.4 µg/ml + 10 µg/ml CHX; 30 ng/ml TNF + 10 µg/ml CHX; or 50 nM ActD) added for 24 hr, and colonies were stained with methylene blue 12 days later. S1P (0.25 µM) was added at the same time as the inhibitors.
(B–D) Colonies from CH11/CHX, TNF/CHX, and ActD treatments are shown. Wells were treated as indicated (top to bottom, left to right): (1) DMSO, (2) 50 µM D609, (3) 20 µM GW4869, (4) 100 µM DOP, (5) 100 µM THI, and (6) 0.25 µM S1P.
All data are reported as ± SD. See also Figure S7.